Presentation of hepatitis B surface antigen-derived peptides to T cells

"Presentation of hepatitis B surface antigen (HBsAg)-derived peptides to T cells" is the process by which fragments of the HBsAg viral protein are processed inside antigen-presenting cells such as dendritic cells and B cells[1][3]. These peptides are loaded onto major histocompatibility complex (MHC) molecules and displayed on the cell surface for recognition by T cell receptors on CD4+ or CD8+ T cells[3][5]. This step is central to the induction of adaptive immune responses, including the activation of cytotoxic T lymphocytes, helper T cells, and ultimately the production of anti-HBs antibodies, which are protective against hepatitis B virus infection[1][5][7]. Dysregulation or exhaustion of this process can contribute to chronic infection and immune evasion[8]. As a process and not a molecule, this is not a conventional therapeutic target, though it is critical for understanding immunity, vaccine development, and immunotherapeutic strategies for hepatitis B.

Other names

HBsAg peptide presentationHBsAg antigen presentation to T cellsAntigen presentation of hepatitis B surface antigen

Not applicable in the sense of drugs targeting a molecule, but generally refers to peptides from HBsAg being processed and presented via MHC class I (activating CD8+ cytotoxic T cells) and MHC class II pathways (activating CD4+ helper T cells)[1][3][5]. Vaccines based on HBsAg rely on this process for the induction of protective immunity[5].